^
    Apply
    Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas. (CHARTHER) (NCT07181785)
    Phase N/A
    Andrés José Maria Ferreri
    Completed
    Last update posted :
    09/18/2025
    Initiation :
    07/12/2022
    Primary completion :
    07/12/2023
    Completion :
    07/12/2023
    BCL2
    Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT07159906)
    Phase 1/2
    First Affiliated Hospital of Zhejiang University
    Not yet recruiting
    Last update posted :
    09/08/2025
    Initiation :
    09/08/2025
    Primary completion :
    08/01/2027
    Completion :
    08/01/2028
    BCL2
    |
    Rituxan (rituximab) • prednisone • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)
    Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach (NCT07147751)
    Phase N/A
    International Extranodal Lymphoma Study Group (...
    Not yet recruiting
    Last update posted :
    08/29/2025
    Initiation :
    04/01/2026
    Primary completion :
    12/01/2029
    Completion :
    12/01/2029
    BCL2
    Primary Prostatic Lymphoma on a 66 Year-old Male in Mexico. (NCT07134504)
    Phase N/A
    Instituto Mexicano del Seguro Social
    Completed
    Last update posted :
    08/21/2025
    Initiation :
    07/20/2025
    Primary completion :
    07/30/2025
    Completion :
    08/01/2025
    BCL2
    Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma (NCT07097363)
    Phase 2
    University of Washington
    Not yet recruiting
    Last update posted :
    07/31/2025
    Initiation :
    01/01/2026
    Primary completion :
    05/31/2030
    Completion :
    05/31/2030
    BCL2
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype (NCT06863402)
    Phase 2
    Roswell Park Cancer Institute
    Not yet recruiting
    Last update posted :
    07/18/2025
    Initiation :
    09/01/2025
    Primary completion :
    04/01/2029
    Completion :
    04/01/2030
    PD-L1
    |
    Keytruda (pembrolizumab) • nemtabrutinib (MK-1026)
    Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells (NCT07042438)
    Phase 2
    City of Hope Medical Center
    Not yet recruiting
    Last update posted :
    06/29/2025
    Initiation :
    01/17/2026
    Primary completion :
    04/13/2028
    Completion :
    04/13/2028
    BCL2
    |
    Yescarta (axicabtagene ciloleucel)
    Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (NCT06905509)
    Phase 2
    University of California, Davis
    Not yet recruiting
    Last update posted :
    04/01/2025
    Initiation :
    08/01/2025
    Primary completion :
    07/01/2028
    Completion :
    08/01/2030
    BCL2
    |
    carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    Zanubrutinib, Chidamide, and Rituximab Induction with or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL (NCT06890585)
    Phase 2
    Li Zhiming
    Not yet recruiting
    Last update posted :
    03/24/2025
    Initiation :
    06/01/2025
    Primary completion :
    12/31/2029
    Completion :
    12/31/2029
    BCL2
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • Epidaza (chidamide)
    Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ (NCT06846463)
    Phase 2
    Virginia Commonwealth University
    Not yet recruiting
    Last update posted :
    02/26/2025
    Initiation :
    06/30/2025
    Primary completion :
    07/31/2029
    Completion :
    07/31/2032
    BCL2 • NOTCH1 • MYD88 • CD79B • CD5
    |
    doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib)
    Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111-218) (NCT05068440)
    Phase 2
    BeiGene
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    08/11/2021
    Primary completion :
    10/21/2025
    Completion :
    10/21/2025
    CD79B
    |
    CD79B mutation • CD79B mutation
    |
    Brukinsa (zanubrutinib)
    TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT05507541)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/19/2023
    Primary completion :
    11/01/2026
    Completion :
    11/01/2027
    PD-L1 • ALK • BCL2 • BCL6 • IRF4
    |
    ALK positive
    |
    Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)